WO2001005821A3 - Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis - Google Patents

Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis Download PDF

Info

Publication number
WO2001005821A3
WO2001005821A3 PCT/EP2000/006558 EP0006558W WO0105821A3 WO 2001005821 A3 WO2001005821 A3 WO 2001005821A3 EP 0006558 W EP0006558 W EP 0006558W WO 0105821 A3 WO0105821 A3 WO 0105821A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral
metastasis
angiogenesis
tumorigenesis
inhibition
Prior art date
Application number
PCT/EP2000/006558
Other languages
French (fr)
Other versions
WO2001005821A2 (en
Inventor
Maria Teresa Bejarano
Original Assignee
Maria Teresa Bejarano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maria Teresa Bejarano filed Critical Maria Teresa Bejarano
Priority to AU58270/00A priority Critical patent/AU5827000A/en
Publication of WO2001005821A2 publication Critical patent/WO2001005821A2/en
Publication of WO2001005821A3 publication Critical patent/WO2001005821A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Various methods of use of viral IL-10s are provided. In particular, the method makes use of fact that viral IL-10 is capable of inhibiting angiogenesis, tumorigenicity, and metastasis.
PCT/EP2000/006558 1999-07-16 2000-07-11 Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis WO2001005821A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU58270/00A AU5827000A (en) 1999-07-16 2000-07-11 Viral il-10 uses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35483399A 1999-07-16 1999-07-16
US09/354,833 1999-07-16
US16362799P 1999-11-04 1999-11-04
US60/163,627 1999-11-04

Publications (2)

Publication Number Publication Date
WO2001005821A2 WO2001005821A2 (en) 2001-01-25
WO2001005821A3 true WO2001005821A3 (en) 2001-07-19

Family

ID=26859813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/006558 WO2001005821A2 (en) 1999-07-16 2000-07-11 Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis

Country Status (2)

Country Link
AU (1) AU5827000A (en)
WO (1) WO2001005821A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295450B1 (en) 2000-09-29 2015-01-28 Merck Sharp & Dohme Corp. Pegylated interleukin-10
WO2002066069A1 (en) * 2001-02-20 2002-08-29 Kansai Technology Licensing Organization Co., Ltd. Remedies for inflammatory/tumor diseases
ES2606034T3 (en) * 2006-09-28 2017-03-17 Merck Sharp & Dohme Corp. Pegylated IL-10 for use in the treatment of lymphoma
DK2379115T3 (en) 2008-12-17 2018-01-29 Merck Sharp & Dohme Preparation and Use of Mono- and Di-PEG-IL-10
AU2014254019B2 (en) 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2014204816A2 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
CA2920679A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
MX2016005915A (en) 2013-11-11 2016-12-16 Armo Biosciences Inc Methods of using interleukin-10 for treating diseases and disorders.
CN106573072A (en) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 Methods of lowering serum cholesterol
AU2015333827A1 (en) 2014-10-14 2017-04-20 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
CA2963995A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
KR20180038553A (en) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 Methods for using interleukin-10 to treat diseases and disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012725A1 (en) * 1991-01-16 1992-08-06 Schering Corporation Treatment of neoplastic disease with interleukin-10
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012725A1 (en) * 1991-01-16 1992-08-06 Schering Corporation Treatment of neoplastic disease with interleukin-10
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BENJAMIN DAVID: "Interleukin-10 (IL-10)", CANCER TREATMENT RESEARCH, vol. 80, 1995, pages 305 - 319, XP000979179 *
BERMAN ROBERT M ET AL: "Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.", JOURNAL OF IMMUNOLOGY, vol. 157, no. 1, 1996, pages 231 - 238, XP002158947, ISSN: 0022-1767 *
CERVENAK LASZLO ET AL: "Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10.", BLOOD, vol. 96, no. 7, 1 October 2000 (2000-10-01), pages 2568 - 2573, XP002159072, ISSN: 0006-4971 *
DE WAAL MALEFYT R ET AL: "THE BIOLOGY OF HUMAN AND VIRAL IL-10", CYTOKINE, vol. 3, no. 5, 1991, pages 500, XP002158949, ISSN: 1043-4666 *
HUANG SUYUN ET AL: "Interleukin 10 Suppresses Tumor Growth and Metastasis of Human Melanoma Cells : Potential Inhibition of Angiogenesis", CLINICAL CANCER RESEARCH, vol. 2, no. 12, December 1996 (1996-12-01), pages 1969 - 1979, XP000979204 *
KUNDU NAMITA ET AL: "Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer.", JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA), vol. 88, no. 8, 1996, pages 536 - 541, XP000979212, ISSN: 0027-8874 *
RICHTER GUENTHER ET AL: "Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration.", CANCER RESEARCH, vol. 53, no. 18, 1993, pages 4134 - 4137, XP002158948, ISSN: 0008-5472 *
STEARNS M E ET AL: "IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression.", INVASION & METASTASIS, vol. 17, no. 2, March 1997 (1997-03-01), pages 62 - 74, XP000979206, ISSN: 0251-1789 *
STEARNS MARK ET AL: "Interleukin 10 (IL-10) Inhibition of Primary Human Prostate Cell-induced Angiogenesis : IL-10 Stimulation of Tissue Inhibitor of Metalloproteinase-1 and Inhibition of Matrix Metalloproteinase (MMP)-2/MMP-9 Secretion", CLINICAL CANCER RESEARCH, vol. 5, January 1999 (1999-01-01), pages 189 - 196, XP000979198 *

Also Published As

Publication number Publication date
AU5827000A (en) 2001-02-05
WO2001005821A2 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
MXPA01006099A (en) Methods and compositions for reducing the permeabilities of subterranean zones.
HK1047743A1 (en) New use and novel n-azabicyclo-amide derivatives.
ZA991951B (en) Compound and its use.
ZA991975B (en) Enzyme inhibitors.
AU1756799A (en) Epoxidation catalyst, its use and epoxidation method in the presence of said catalyst
ZA991953B (en) Detection of fermentation-related microorganisms.
WO2001005821A3 (en) Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis
GB9817055D0 (en) Reverse transcription and amplification processes and primers therefore
MXPA01011145A (en) Method for the preservation of viruses and mycoplasma.
AU2001245288A1 (en) Overhanging form system and method of using the same
MXPA01009950A (en) Material handling system and method of operating the same.
IL140927A0 (en) Perforator for weblike materials with means for modifying the interval between consecutive lines of perforations
MXPA02012896A (en) Combinations of statins, estrogenic agents and optionally estrogens.
EG23373A (en) Process and intermediates.
GC0000152A (en) Downhole pulser.
HK1046002B (en) Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
ZA200205098B (en) Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
ZA200007405B (en) Angiogenesis inhibitors.
MXPA03004614A (en) Post-crepe stabilized material and method of producing the same.
MXPA03001557A (en) Biphenyl derivatives and the use thereof as integrin inhibitors.
AU2581700A (en) Sandfilter device for use in the recovery of oil, gas and water
AU1435899A (en) Epoxidation catalyst, its use and epoxidation method in the presence of said catalyst
AU5571799A (en) Angiogenesis inhibitors and uses thereof
HK1053825A1 (en) Hydrazide and alkoxyamide angiogenesis inhibitors.
ZA200003708B (en) Diamond semiconductor and method for the fabrication thereof.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP